Name | 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropionic acid |
Synonyms | FA Fenofibric acid FENOFIBRIC ACID FENOFIBRATE ACID Fenofibrate Acid SALOR-INT L498335-1EA LABOTEST-BB LT00239222 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropionic acid 2-[4-(4-CHLOROBENZOYL)PHENOXY]-2-METHYLPROPANOIC ACID 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-Propanoic acid 2-[4'-(p-Chlorobenzoyl)phenoxy]-2-methylpropionic acid 2-[4-(4-CHLOROBENBONYZOYL)PHENOXY)-2-METHYLPROPIONIC ACID 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate 2-[4-(4-CHLORO-BENZOYL)-PHENOXY]-2-METHYL-PROPIONIC ACID (FENOFIBRIC ACID) |
CAS | 42017-89-0 |
EINECS | 255-626-9 |
InChI | InChI=1/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)/p-1 |
Molecular Formula | C17H15ClO4 |
Molar Mass | 318.75 |
Density | 1.286±0.06 g/cm3(Predicted) |
Melting Point | 177-179°C |
Boling Point | 486.5±35.0 °C(Predicted) |
Flash Point | 248°C |
Solubility | Chloroform (Slightly), Methanol (Slightly) |
Vapor Presure | 2.82E-10mmHg at 25°C |
Appearance | White to white-like solid |
Color | White to Off-White |
BRN | 2058973 |
pKa | 3.09±0.10(Predicted) |
Storage Condition | 2-8°C |
MDL | MFCD00792461 |
In vitro study | Fibric acids, the activated form of lipid-lowering drugs, are also agonists of PPAR alpha, which has the effect of raising high-density lipoprotein. Fibriic acids enhance fatty acid catabolism and lower blood lipid levels-primarily triglyceride levels. It upregulates ABCA1 expression and apoA-I-mediated HDL production. The Fibric acids exert their effect on ABCA1 expression by enhancing the transcription of the LXR-dependent ABCA1 gene. |
In vivo study | Fenofibriic acid attenuates the abnormal increase of circulating endothelial progenitor cells (EPC) in OIR mice. Its inhibitory effect on EPC mobilization is dependent on PPAR α. Fenofibriic acid inhibits hypoxia-induced increase in retinal endothelial progenitor cells, reduces the number of circulating CXCR4 positive EPC, down-regulates serum SDF-1 levels and inhibits the overexpression of HIF-1a and SDF-1 in the retina. |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R22 - Harmful if swallowed |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. S60 - This material and its container must be disposed of as hazardous waste. S24/25 - Avoid contact with skin and eyes. |
UN IDs | UN 3077 9 / PGIII |
WGK Germany | 3 |
RTECS | UA2453000 |
HS Code | 29189900 |
Hazard Class | 9 |
Packing Group | III |
Toxicity | LD50 oral in rat: 1242mg/kg |
biological activity | Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a lipid-lowering agent that reduces low density lipoprotein cholesterol and triglyceride. |
Target | Value |
Use | Used as a pharmaceutical intermediate An intermediate of fenofibrate. Fenofibric acid is the active metabolite of Fenofibrate (F248640). Increases Apolipoprotein A- I holmium ediated High-Density Lipoprotein Biogenesis by enhancing transcription of ATP-Binding cassette transpor ter A1 gene in a liver X receptor holmium ependent banner. |